Jade Biosciences (JBIO) EBIT (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of EBIT data on file, last reported at -$43.4 million in Q1 2026.

• Quarterly EBIT fell 85.79% year-over-year to -$43.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.6 million (down 32.75% YoY) and the FY2025 annual result came in at -$113.5 million, down 52.21% from the prior year.
• EBIT eased to -$43.4 million in Q1 2026, from -$35.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$11.0 million in Q1 2022 to a low of -$43.4 million in Q1 2026.
• A 5-year average of -$23.1 million and a median of -$22.1 million in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT slumped 296.37% — and 2024, when it grew 27.2%.
• Tracing JBIO's EBIT over 5 years: stood at -$15.9 million in 2022, then plunged by 39.2% to -$22.1 million in 2023, then plunged by 61.05% to -$35.5 million in 2024, then rose by 1.57% to -$35.0 million in 2025, then slipped by 24.2% to -$43.4 million in 2026.
• The last three EBIT figures came in at -$43.4 million (Q1 2026), -$35.0 million (Q4 2025), and -$27.4 million (Q3 2025), per Business Quant data.